Latest Stock Market News

In 2024, the Reserve Bank of India expanded its gold reserves by 72.6 tonnes, reaching a total of 876.18 tonnes valued at $66.2 billion. This increase is the highest since 2021 and the second highest since 2017. The central bank s gold purchases help protect against currency volatility and enhance valuation gains on reserves.

Ashu Khullar, Citi’s India chief, is appointed as the global co-head of GAM, based in London, and will oversee EMEA and Asia. K Balasubramanian will succeed him as India s CEO, pending RBI approval. During Khullar s tenure, Citi s revenue grew significantly, reflecting his effective leadership.

Banks are focusing on medium-term deposit mobilization to comply with new liquidity coverage ratio rules and improve asset-liability management. Non-callable deposits with two-to-five year maturities are preferred despite higher costs. Revised rules effective from April 1 mandate a higher run-off factor, prompting banks to invest more in liquid securities.

The advance helped the benchmarks cut all their losses in 2025, though analysts are guarded about concluding that the recovery is here to stay. The outcome of the Reserve Bank of India s monetary policy meeting on Friday will be the next trigger for the market.

Under the framework, the facility of algo trading would be provided by the stockbroker to retail investors only after obtaining permission of the stock exchange for each algo.

​​According to a Motilal Oswal Financial Services study, 27 out of 47 companies on the Nifty were trading above their 10-year average valuations. The valuations were measured based on the Price to Earnings (PE) Ratio and Price to Book (P/B).

The dollar index was at 108.52, versus 109.8 on Monday. The appreciation in the local currency comes after the rupee closed a record low of 87.18 per dollar on Monday. The rupee was in a tight range throughout the day on Tuesday. It traded between 87/$1 and 87.13/$1. Most Asian currencies also appreciated in response to a slight correction in the dollar index.

Raw material costs stood at 57.7% of the consolidated revenues-higher than the year-ago level of 56.5%. Other expenses, too, climbed to make up 16.2% of the revenues-much higher than the y-o-y level of 14.8%. These increased expenses, and a less favourable product mix, dented profitability.

Gland Pharma share price: Revenue from operations fell 10% year-on-year to Rs 1,384 crore. EBITDA increased by 1% year-on-year to Rs 360 crore, with margins improving by 300 basis points to 26%. R&D expenses were Rs 43.7 crore, making up 4.3% of the revenue.

JB Pharma on Tuesday reported a 22% year-on-year (Y-o-Y) jump in net profit to Rs 162 crore for the quarter ended December 31 led by strong growth in domestic formulation business.